CSIMarket
 


Zyla Life Sciences  (EGLT)
Other Ticker:  
 

Zyla Life Sciences's Leverage Ratio

EGLT's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 8.93%, Leverage Ratio fell to 8.29, above the Zyla Life Sciences's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the first quarter 2020, 320 other companies have achieved lower Leverage Ratio than Zyla Life Sciences in the I Quarter 2020. While Leverage Ratio total ranking has deteriorated compared to the forth quarter 2019 from 3604 to 4156 .

Explain Leverage Ratio?
Who are EGLT Customers?
What are EGLT´s Total Liabilities?


EGLT Leverage Ratio (Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Equity Change -67.72 % - - - -
Y / Y Total Liabilities Change 8.74 % 8.48 % 15.61 % 24.11 % 30.46 %
Leverage Ratio MRQ 8.29 4.43 3.94 3.08 2.46
EGLT's Total Ranking # 4156 # 3604 # 2428 # 3122 # 2624
Seq. Equity Change -41.74 % -12.42 % -16.08 % -24.61 % -
Seq. Total Liabilities Change 8.93 % -1.39 % 7.17 % -5.54 % 8.67 %



Leverage Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 321
Healthcare Sector # 785
Overall Market # 4156


Leverage Ratio Statistics
High Average Low
20.57 3.4 0.17
(Dec 31 2016)   (Mar 31 2014)




Financial Statements
Zyla Life Sciences's Equity $ 25 Millions Visit EGLT's Balance sheet
Zyla Life Sciences's Total Liabilities $ 205 Millions Visit EGLT's Balance sheet
Source of EGLT's Sales Visit EGLT's Sales by Geography


Cumulative Zyla Life Sciences's Leverage Ratio

EGLT's Leverage Ratio for the trailling 12 Months

EGLT Leverage Ratio

(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
Y / Y Equity TTM Growth -67.72 % - - - -
Y / Y Total Liabilities TTM Growth 8.74 % 8.48 % 15.61 % 24.11 % 30.46 %
Leverage Ratio TTM 4.4 3.31 10.25 - -
Total Ranking TTM # 268 # 2767 # 169 # 3122 # 2624
Seq. Equity TTM Growth -41.74 % -12.42 % -16.08 % -24.61 % -
Seq. Total Liabilities TTM Growth 8.93 % -1.39 % 7.17 % -5.54 % 8.67 %


On the trailing twelve months basis Due to the net new borrowings of 8.93% during the trailing twelve months finishing in the I Quarter 2020, cumulativeLeverage Ratio improved to 4.4, above the Zyla Life Sciences's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 42, during the past 12 months, other companies have achieved lower Leverage Ratio than Zyla Life Sciences. While Leverage Ratio total ranking has improved so far to 268, from total ranking in previous 12 month period at 2767.

Explain Leverage Ratio?
Who are EGLT Customers?
What are EGLT´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 43
Healthcare Sector # 70
Within the Market # 268


trailing twelve months Leverage Ratio Statistics
High Average Low
5.43 1.68 0.08
(Mar 31 2017)   (Mar 31 2015)




Companies with similar Leverage Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Leverage RatioMar 31 2020 MRQ Total LiabilitiesMar 31 2020 MRQ Equity
Puma Biotechnology Inc   19.86 $ 186.222  Millions$ 9.377  Millions
Dynavax Technologies Corporation  17.80 $ 210.460  Millions$ 11.824  Millions
Evofem Biosciences Inc   14.32 $ 14.624  Millions$ 1.021  Millions
Vincerx Pharma Inc   12.30 $ 61.510  Millions$ 5.000  Millions
Redhill Biopharma Ltd   12.00 $ 166.377  Millions$ 13.864  Millions
Amneal Pharmaceuticals Inc   9.91 $ 3,999.905  Millions$ 403.458  Millions
Eli Lilly And Company  9.74 $ 31,133.900  Millions$ 3,197.200  Millions
Ibio inc   9.67 $ 38.254  Millions$ 3.957  Millions
Cannapharmarx Inc   9.50 $ 12.049  Millions$ 1.269  Millions
Zyla Life Sciences  8.29 $ 204.783  Millions$ 24.696  Millions
Statera Biopharma Inc fka Cytocom Inc   7.80 $ 6.078  Millions$ 0.779  Millions
Liminal Biosciences Inc   6.85 $ 78.723  Millions$ 11.499  Millions
Obseva Sa  6.83 $ 57.093  Millions$ 8.354  Millions
Wave Life Sciences Ltd   6.15 $ 128.376  Millions$ 20.858  Millions
Portola Pharmaceuticals inc   6.13 $ 441.273  Millions$ 72.033  Millions
Forte Biosciences Inc   6.07 $ 12.638  Millions$ 2.082  Millions
Lexicon Pharmaceuticals Inc   5.77 $ 315.790  Millions$ 54.777  Millions
Avadel Pharmaceuticals Plc  5.48 $ 175.658  Millions$ 32.067  Millions
Scynexis Inc   5.42 $ 35.014  Millions$ 6.455  Millions
Cytomx Therapeutics Inc   5.26 $ 366.895  Millions$ 69.767  Millions
Carisma Therapeutics Inc   4.67 $ 86.214  Millions$ 18.451  Millions
Bellerophon Therapeutics inc  4.40 $ 9.432  Millions$ 2.146  Millions
Jaguar Health inc   4.34 $ 27.043  Millions$ 6.233  Millions
Durect Corp  4.27 $ 60.049  Millions$ 14.074  Millions
Organogenesis Holdings Inc   4.17 $ 168.045  Millions$ 40.295  Millions
Aveo Pharmaceuticals Inc   4.12 $ 28.888  Millions$ 7.008  Millions
Integrated Biopharma Inc  3.98 $ 16.501  Millions$ 4.144  Millions
Optinose Inc   3.96 $ 139.039  Millions$ 35.131  Millions
Intelgenx Technologies Corp   3.68 $ 9.993  Millions$ 2.714  Millions
Precigen Inc   3.64 $ 317.443  Millions$ 87.229  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com